

Jones Peter (Orcid ID: 0000-0003-1560-1186)
Kelly Anne-Maree (Orcid ID: 0000-0002-4655-5023)
CRAIG SIMON (Orcid ID: 0000-0003-2594-1643)
Kuan Win Sen (Orcid ID: 0000-0002-2134-7842)

Chronic disease management in Emergency Department patients presenting with dyspnoea.

Corresponding Author

Peter Jones PhD

Department of Emergency Medicine, Auckland City Hospital, and Department of Surgery, University of Auckland, Park Road, Grafton, Auckland, New Zealand

Email: PeterJ@adhb.govt.nz

Other Authors

Anne Maree Kelly FACEM

Joseph Epstein Centre for Emergency Medicine Research, St Albans, Victoria, Australia and School of Medicine –Western Clinical School, The University of Melbourne, Parkville, Victoria, Australia. Email: anne-maree.kelly@wh.org.au

Gerben Keijzers PhD

Department of Emergency Medicine, Gold Coast University Hospital, Gold Coast, QLD, Australia and School of Medicine, Bond University, Gold Coast, QLD, Australia and School of Medicine, Griffith University, Gold Coast, QLD, Australia Email: Gerben.Keijzers@health.qld.gov.au

Sharon Klim BN PGDipAcuteCareNurs(Emerg)

Joseph Epstein Centre for Emergency Medicine Research @ Western Health, Sunshine, Australia
Email: Sharon.klim@wh.org.au

This is the author manuscript accepted for publication and has undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: [10.1111/1742-6723.13625](https://doi.org/10.1111/1742-6723.13625)

Anna Holdgate FACEM

Department of Emergency Medicine, Liverpool Hospital, Sydney, Australia and University of New South Wales (Southwest Clinical School), Sydney, Australia Email:

Anna.Holdgate@sswahs.nsw.gov.au

Colin A Graham MD

Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong SAR. Email:

cagraham@cuhk.edu.hk

Simon Craig MPH

Emergency Department, Monash Medical Centre, Clayton, Australia; School of Clinical Sciences, Monash University, Clayton, Australia and Murdoch Children's Research Institute, Parkville, Australia

Email: Simon.Craig@monashhealth.org

Win Sen Kuan MRCSEd(A&E)

Emergency Medicine Department, National University Health System, Singapore and Department of Surgery, Yong Loo Lin School of Medicine, National University of Singapore Email:

win_sen_kuan@nuhs.edu.sg

Said Laribi MD, PhD

Tours University, School of Medicine and Tours University hospital, Emergency Medicine Department, Tours, France

Email: S.LARIBI@chu-tours.fr

AANZDEM study group (see acknowledgements)

Abstract

Introduction: Guideline recommended treatments for chronic conditions are thought to reduce ED presentations.

Method: We used data from 1958 ED patients with dyspnoea to describe medication use in people with chronic conditions.

Results: 1233 (63.5%) patients had one or more of: COPD 547 (28%); asthma 454 (23%); AF 368 (19%) or HF 401 (21%). Approximately 70% were prescribed appropriate preventative medication for their chronic condition when they presented to ED with dyspnoea.

Conclusion: Prescription of guideline recommended therapies for chronic conditions in patients presenting to the ED in Australasia with acute dyspnoea is similar or higher than reported previously.

Key Words

Emergencies

Chronic Disease

Drug Therapy

Preventative Medicine

Dyspnoea

Introduction

Clinical practice guidelines inform therapeutic decision-making for management of chronic medical conditions including chronic obstructive pulmonary disease (COPD), asthma, atrial fibrillation (AF) and heart failure (supplementary file). These guidelines aim to promote uptake of evidence-based

practice to optimise patient care and improve quality of life, reduce emergency department (ED) attendances and reduce hospital admissions.

There is limited data regarding medication use in patients with these chronic conditions presenting to the ED. Data from our large study of patients attending ED with dyspnoea as a main symptom¹ afforded us the opportunity to explore chronic medication use in the sub-group of that population with the defined chronic conditions. The aim of this study was to describe routine medication use in patients presenting to ED with dyspnoea with COPD, asthma, AF or HF.

Methods

This was a sub-study of a prospective, international cohort study undertaken in 2014, with methods previously reported.¹ Ethics approvals were obtained for all sites according to local requirements.

Outcomes of interest and analysis

The primary outcome was the proportion of patients receiving guideline recommended preventative pharmacotherapy. The secondary outcome was the reason for presentation to ED. The analysis was descriptive, using SPSS v25, IBM corporation, Armonk, NY, USA

Results

The table shows the demographics, co-morbidities, medication use and reason for ED presentation. The mean (95%CI) age was 65 (64-66) years and 54% (52-56%) were female. Co-morbidities were common, with 1233/1958 (63.5%) having more than one chronic condition. Appropriate preventative treatments were prescribed for 400/547 (73%) COPD, 273/454 (60%) asthma, 270/368 (73%) AF and 372/401 (93%) HF patients. The full list of medications for each group is shown in the supplementary file. Approximately half of the time, people with a known chronic condition presented with an exacerbation of that condition. The other reasons for presentation with acute shortness of breath in this cohort were mostly due to an exacerbation of one of the other chronic

conditions studied, or respiratory tract infections (20%), as shown in the table. Other causes of shortness of breath were uncommon. These included acute coronary syndromes (49), pulmonary embolism (33), anaemia (28), interstitial/other chronic lung disease (19), malignancy (19), non-respiratory sepsis (17), pneumothorax (14), allergy (14), and drugs/toxins (10).

Discussion

Compliance with guideline recommended therapy for chronic conditions for patients presenting to the ED in Australasia with acute shortness of breath was similar or higher in 2014 than that reported previously. Three quarters of patients with COPD were on preventative treatment, at the high end of rates reported in other studies (supplementary file). Three quarters of patients with a history of AF were on rate control medication. Although lower than rates from an AF registry study in Korea,² this is not unexpected given our cohort was an unselected group of AF patients. Two thirds of AF patient were on stroke prevention medications, which is higher than previously reported. Almost all HF patients were on treatment, which is higher than previously reported rates (supplementary file). Provider adherence to guidelines improves when providers are aware of the guideline and believe it applies to their patients.³ Adherence is also improved when the guideline is clear, supported by management, implementation is resourced appropriately, feedback is given, and that there is teamwork and a commitment to quality improvement.³

Patient compliance with medication is complex. In some but not all settings, beliefs about health, treatments, cultural influences, patient-prescriber relationships, and perceptions of illness control were important.⁴

A systematic review of cost effectiveness studies across many chronic conditions found few studies and inconsistent evidence for the cost effectiveness of interventions to improve COPD/Asthma and HF compliance.⁵

Although the current study suggests there may be some room for improvement in compliance for patients with chronic disease presenting to the ED with dyspnoea, it is unclear whether interventions would be beneficial or cost effective in this cohort of patients with respect to reducing subsequent ED presentations. Further research is recommended to determine whether this is the case and what role ED may have in this regard.

Limitations

As a retrospective study we were not able to confirm that patients were compliant with treatments prescribed, and the true compliance with long term medications may be lower than the prescription rate reported here. Our findings only relate to the cohort and time studied, so may not represent compliance in the wider community.

Conclusion

Our study found that prescriptions for guideline recommended therapy for chronic conditions for patients presenting to the ED in Australasia with acute shortness of breath was similar or higher in 2014 than reported previously.

Acknowledgements

AANZDEM study group:

Richard McNulty (Blacktown and Mt Druitt Hospitals NSW), Clifford Tan (Canterbury Hospital), David Lord Cowell (Dubbo Hospital NSW), Anna Holdgate and Nitin Jain (Liverpool Hospital NSW), Tracey

Devillecourt (Nepean Hospital NSW), Alan Forrester and Kendall Lee (Port Macquarie Hospital NSW), Dane Chalkley (Royal Prince Alfred Hospital NSW), Mark Gillett and Lydia Lozzi (Royal North Shore Hospital NSW), Stephen Asha (St George Hospital NSW), Martin Duffy (St Vincent's Hospital Sydney NSW), Gina Watkins (Sutherland Hospital NSW), Richard Stone (Cairns Hospital, QLD), David Rosengren (Greenslopes Private Hospital QLD), Jae Thone (Gold Coast University Hospital QLD), Shane Martin (Ipswich Hospital QLD), Ulrich Orda (Mt Isa Hospital QLD), Ogilvie Thom (Nambour Hospital QLD), Frances Kinnear (Prince Charles Hospital QLD), Rob Eley (Princess Alexandra Hospital QLD), Alison Ryan (Queen Elizabeth II Jubilee Hospital QLD), Douglas Morel (Redcliffe Hospital QLD), Christopher May (Redlands Hospital QLD), Jeremy Furyk (Townsville Hospital QLD), Graeme Thomson (Angliss Hospital VIC), Simon Smith & Richard Smith (Bendigo Hospital VIC), Andrew Maclean and Michelle Grummisch (Box Hill Hospital VIC), Alistair Meyer (Casey Hospital VIC) Robert Meek (Dandenong Hospital VIC), Pamela Rosengarten (Frankston Hospital VIC), Barry Chan and Helen Haythorne (Knox Private Hospital VIC), Peter Archer (Maroondah Hospital VIC), Simon Craig & Kathryn Wilson (Monash Medical Centre VIC), Jonathan Knott (Royal Melbourne Hospital VIC), Peter Ritchie (Sunshine Hospital VIC), Michael Bryant (Footscray Hospital VIC), Stephen MacDonald (Armadale Hospital WA), Tom Lee (Joondalup Health Campus Hospital WA), Mlungisi Mahlangu (Peel Health WA), David Mountain (Sir Charles Gairdner Hospital WA), Ian Rogers (St John of God Murdoch Hospital WA), Tobias Otto (Queen Elizabeth Hospital SA, Peter Stuart and Jason Bament (Modbury Hospital SA), Michelle Brown (Royal Hobart Hospital TAS), Peter Jones (Auckland City Hospital New Zealand), Renee Greven-Garcia (Hawkes Bay Hospital New Zealand), Michael Scott (Hutt Valley Hospital New Zealand), Thomas Cheri (Palmerston North Hospital New Zealand), Mai Nguyen (Wellington Regional Hospital New Zealand), Colin Graham (Prince of Wales Hospital Hong Kong), Chi-Pang Wong and Tai Wai Wong (Pamela Youde Nethersole Eastern Hospital Hong Kong), Ling-

Pong Leung (Queen Mary Hospital Hong Kong), Chan Ka Man (Tuen Mun Hospital Hong Kong), Ismail Mohd Saiboon (Hospital Universiti Kebangsaan Malaysia), Nik Hisamuddin Rahman (Hospital Universiti Sains Malaysia), Wee Yee Lee (Changi General Hospital Singapore), Francis Chun Yue Lee (Khoo Teck Puat Hospital Singapore), Win Sen Kuan (National University Hospital Singapore), Sharon Klim, Kerrie Russell & Anne-Maree Kelly (AANZDEM co-ordinating centre), Gerben Keijzers, & Said Laribi (steering committee) and Charles Lawoko (ATN Universities, statistician).

Author contributions: PJ design, recruitment analysis, manuscript preparation and revision; AMK concept, design, recruitment, analysis, manuscript preparation; AH, GK, CAG, SC, WSK, SL design, recruitment, refinement of manuscript, SK design, data management, refinement of manuscript.

Conflict of interest: GK, SC and PJ are section editors for Emergency Medicine Australasia. AMK is a member of the Editorial Board of Emergency Medicine Australasia.

Funding: The The Asia, Australia, and New Zealand Dyspnea in Emergency Departments Study (AANZDEM) study was part funded by the Emergency Medicine Foundation (formerly Queensland Emergency Medicine Research Foundation, grant number EMPJ-108R2 1-2014).

References

1. Kelly AM, Keijzers G, Klim S, Graham CA, Craig S, Kuan WS, et al. An Observational Study of Dyspnea in Emergency Departments: The Asia, Australia, and New Zealand Dyspnea in Emergency Departments Study (AANZDEM). *Academic emergency medicine : official journal of the Society for Academic Emergency Medicine*. 2017;24(3):328-36.
2. Kim H, Kim TH, Cha MJ, Lee JM, Park J, Park JK, et al. A Prospective Survey of Atrial Fibrillation Management for Real-world Guideline Adherence: COmparison study of Drugs for symptom control and complication prEvention of Atrial Fibrillation (CODE-AF) Registry. *Korean Circ J*. 2017;47(6):877-87.
3. Ward MM, Yankey JW, Vaughn TE, BootsMiller BJ, Flach SD, Watrin S, et al. Provider adherence to COPD guidelines: relationship to organizational factors. *Journal of evaluation in clinical practice*. 2005;11(4):379-87.
4. Lemay J, Waheedi M, Al-Sharqawi S, Bayoud T. Medication adherence in chronic illness: do beliefs about medications play a role? *Patient preference and adherence*. 2018;12:1687-98.
5. Oberje EJ, de Kinderen RJ, Evers SM, van Woerkum CM, de Bruin M. Cost effectiveness of medication adherence-enhancing interventions: a systematic review of trial-based economic evaluations. *Pharmacoeconomics*. 2013;31(12):1155-68.

Table: Demographics, Co-morbidities, Medications and Reason for ED Presentation

	COPD	Asthma	Atrial Fibrillation	Heart Failure
	n=547	n=454	n=368	n=401
Demographics				
Age (median, IQR)	75, 65-82	57, 38-73	81, 70-87	80, 69-88
Sex (N male, %, 95% CI)	298, 54%, 50-59%	159, 35%, 31-46%	193, 52%, 47-58%	206, 51%, 46-56%
Co-morbidities (N, %, 95% CI)				
Hypertension	310, 57%, 52-61%	170, 37%, 33-42%	239, 65%, 60-70%	261, 65%, 60-70%
Ischaemic heart disease	194, 35%, 31-40%	77, 17%, 14-21%	145, 39%, 35-44%	206, 51%, 46-56%
Dyslipidaemia	210, 38%, 34-43%	104, 23%, 19-27%	167, 45%, 40-50%	183, 46%, 41-51%
Diabetes	138, 25%, 22-29%	88, 19%, 16-23%	111, 30%, 27-35%	162, 40%, 36-45%
Smoker (Active/Recent)	120, 22%, 19-26%	89, 20% 16-24%	32, 9%, 6-12%	39, 10%, 7-13%
Heart Failure	164, 30%, 26-34%	56, 12%, 9-15%	179, 49%, 44-54%	-
Atrial Fibrillation	118, 21%, 18-25%	45, 10%, 7-13%	-	179, 45%, 40-50%
Chronic Obstructive Pulmonary Disease	-	86, 19%, 16-23%	118, 32%, 28-37%	164, 41%, 36-46%
Asthma	86, 16%, 13-19%	-	45, 12%, 9-16%	56, 14%, 11-18%
Prescribed Medications (N, %, 95% CI)				
Any Heart Failure Medication	384, 70%, 66-74%	186, 41%, 37-46%	323, 88%, 84-91%	372, 93%, 90-95%
Any Rate Control Medication	249, 45%, 41-50%	113, 25%, 21-29%	270, 73%, 68-78%	270, 67%, 63-72%
Long-acting anticoagulant	97, 18%, 15-21%	47, 11%, 8-14%	199, 54%, 49-59%	128, 32%, 28-37%
Any Respiratory Preventer	452, 83%, 79-86%	368, 81%, 77-84%	160, 43%, 39-49%	187, 47%, 42-52%
<i>Respiratory Preventer (excluding B-agonist)*</i>	400, 73%, 69-77%	273, 60%, 56-65%	141, 38%, 33-43%	156, 39%, 34-44%
Primary Diagnoses for ED Presentation (N, %, 95% CI)				
COPD acute exacerbation	274, 50%, 46-54%	52, 12%, 9-15%	49, 13%, 10-17%	66, 16%, 13-20%
Asthma acute exacerbation	12, 2%, 1-4%	190, 42%, 37-46	9, 2%1-5%	8, 2%, 1-4%
Atrial fibrillation	7, 1%, 0-3%	7, 1%, 0-3%	22, 6%, 4-9%	8, 2%, 1-4%
Heart failure acute exacerbation	75, 14%, 11-17%	34, 7%, 5-10%	144, 39% 34-44%	188, 47%, 42-52%
Respiratory Infection	100, 18%, 15-22%	102, 22%, 19-27%	76, 21%, 17-25%	65, 16%, 13-20%
Other	79, 14%, 12-18%	69, 15%, 12-19%	68, 18%, 15-23%	66, 16%, 13-20%

Key: *It was not known if the beta-agonist was short or long acting **some patients on dual antiplatelet agents. **Bold** font indicates treatment appropriate for the particular chronic condition or presentation due to the chronic condition as appropriate. ED=Emergency Department , COPD=Chronic Obstructive Pulmonary Disease

Supplementary File

Supplementary Table 1: Medication use in Patients with Chronic Conditions

	COPD	Asthma	Atrial Fibrillation	Heart Failure
	n=547	n=454	n=368	n=401
Chronic medications (N, %, 95% CI)				
Any Heart Failure Medication	384, 70%, 66-74%	186, 41%, 37-46%	323, 88%, 84-91%	372, 93%, 90-95%
Any Rate Control Medication	249, 45%, 41-50%	113, 25%, 21-29%	270, 73%, 68-78%	270, 67%, 63-72%
Long-acting anticoagulant	97, 18%, 15-21%	47, 11%, 8-14%	199, 54%, 49-59%	128, 32%, 28-37%
Any Respiratory Preventer	452, 83%, 79-86%	368, 81%, 77-84%	160, 43%, 39-49%	187, 47%, 42-52%
<i>Respiratory Preventer (excluding B-agonist)*</i>	400, 73%, 69-77%	273, 60%, 56-65%	141, 38%, 33-43%	156, 39%, 34-44%
Specific Medications				
Diuretic	211, 39%, 35-43%	90, 20%, 16-24%	211, 57%, 52-62%	300, 75%, 70-79%
Nitrates	65, 12%, 10-15%	24, 6%, 4-8%	47, 13%, 10-17%	73, 18%, 15-22%
Beta blocker	149, 27%, 24-31%	60, 13%, 10-17%	173, 47%, 42-52%	219, 55%, 50-60%
Cardiac glycoside	53, 10%, 7-13%	12, 3%, 1-5%	95, 26%, 22-31%	57, 14%, 11-18%
ACE inhibitor	224, 41%, 37-45%	124, 27%, 23-32%	175, 48%, 43-53%	212, 53%, 48-58%
Aldosterone antagonist	54, 10%, 8-13%	15, 3%, 2-5%	43, 12%, 9-15%	66, 16%, 13-21%
Calcium channel antagonist	109, 20%, 17-23%	61, 13%, 11-17%	79, 21%, 18-26%	73, 18%, 15-22%
Other anti-arrhythmic	38, 7%, 5-9%	9, 2%, 1-4%	76, 21%, 17-25%	60, 15%, 12-19%
Statin	247, 45%, 41-49%	114, 25%, 21-29%	190, 52%, 47-57%	205, 51%, 46-56%
Aspirin	190, 35%, 31-39%	72, 16%, 13-20%	131, 36%, 31-41%	165, 41%, 36-46%
Clopidogrel	77, 14%, 11-17%	29, 6%, 4-9%	39, 11%, 8-14%	64, 16%, 13-20%
Any antiplatelet agent**	227, 42%, 37-46%	97, 21%, 18-25%	153, 42%, 37-47%	196, 49%, 44-54%
Long-acting anticoagulant	97, 18%, 15-21%	47, 11%, 8-14%	199, 54%, 49-59%	128, 32%, 28-37%
Inhaled beta-agonist	401, 73%, 69-77%	332, 73%, 69-77%	123, 33%, 29-38%	151, 38%, 33-43%
Inhaled anticholinergic agent	280, 51%, 47-55%	90, 20%, 16-24%	62, 17%, 13-21%	78, 20%, 16-24%
Inhaled corticosteroid	272, 50%, 45-54%	221, 49%, 44-53%	97, 37%, 22-31%	108, 27%, 23-32%
Xanthine	12, 2%, 1-4%	10, 2%, 1-4%	4, 1%, 0-3%	6, 2%, 0-3%
Leukotriene receptor antagonist	7, 1%, 0-3%	6, 1%, 0-3%	1, 0%, 0-2%	3, 1%, 0-3%
Oral corticosteroid	88, 16%, 13-20%	63, 14%, 11-17%	31, 8%, 6-12%	39, 10%, 7-13%
Home oxygen	205, 51%, 46-56%	14, 3%, 2-5%	17, 5%, 3-7%	39, 10%, 7-13%

Key: *It was not known if the beta-agonist was short or long acting **some patients on dual antiplatelet agents. **Bold** font indicates treatment appropriate for the particular chronic condition. COPD=Chronic Obstructive Pulmonary Disease

Supplementary Table 2: Previous rates of compliance with medications in chronic conditions and relevant references

Condition	Compliance	References (full reference in list below table)
COPD	53-78%	Aaron 2007; Khmour 2009; Dhamane 2016; Neugaard 2011; Yang 2012; Karner 2014 Alsaedi 2002
Asthma	50-80%	Williams 2004; Souza-Machado 2010; Calverly 2004; Peytremann-Bridevaux 2015; Chauhan 2015; Gatheral 2017
AF	50-90%	Kim 2017; Oramiro 2018
Heart Failure	28-80%	Neugaard 2011; Fitzgerald 2011; Tsuyuki 2001; Unverzagt 2016; Faris 2012; Flather 2000; Ruppar 2016

Reference List

The reference list is provided below as journal restrictions for the Short Report section only allow five references in the published manuscript. Readers with an interest in the topic may find this extended reference list useful.

Examples of Guidelines

1. Yang IA, Dabscheck EJ, George J, Jenkins SC, McDonald CF, McDonald VM, Smith BJ, NA Z. COPD-X Concise Guide for Primary Care: Lung Foundation Australia; 2018 [Accessed 22/1/2019]. Available from: https://copdx.org.au/wp-content/uploads/2015/08/LFA-COPD-X-doc_V3.02_0815_WEB.pdf.
2. Australian Asthma Handbook v1.3 National Asthma Council; 2019 [Accessed 22/1/2019]. Available from: <http://www.astmahandbook.org.au/>.
3. Brieger D, Amerena J, Attia J, Bajorek B, Chan KH, Connell C, Freedman B, Ferguson C, Hall T, Haqqani H, Hendriks J, Hespe C, Hung J, Kalman JM, Sanders P, Worthington J, Yan TD, Zwar N. National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand: Australian Clinical Guidelines for the Diagnosis and Management of Atrial Fibrillation 2018. Heart, lung & circulation. 2018;27(10):1209-66.
4. Atrial fibrillation: management (CG180): National Institute for Health and Care Excellence; 2014 [Accessed 22/1/2019]. Available from: <https://www.nice.org.uk/guidance/cg180/>.
5. Atherton JJ, Sindone A, De Pasquale CG, Driscoll A, MacDonald PS, Hopper I, Kistler PM, Briffa T, Wong J, Abhayaratna W, Thomas L, Audehm R, Newton P, O'Loughlin J, Branagan M, Connell C. National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Guidelines for the Prevention, Detection, and Management of Heart Failure in Australia 2018. Heart, lung & circulation. 2018;27(10):1123-208.

Original AANZDEM Study and Published Protocol

6. Kelly AM, Keijzers G, Klim S, Graham CA, Craig S, Kuan WS, Jones P, Holdgate A, Lawoko C, Laribi S. An Observational Study of Dyspnea in Emergency Departments: The Asia, Australia, and New Zealand Dyspnea in Emergency Departments Study (AANZDEM). Academic emergency medicine : official journal of the Society for Academic Emergency Medicine. 2017;24(3):328-36.

7. Kelly AM, Keijzers G, Klim S, Graham CA, Craig S, Kuan WS, Jones P, Holdgate A, Lawoko C, Laribi S. Asia, Australia and New Zealand Dyspnoea in Emergency Departments (AANZDEM) study: Rationale, design and analysis. *Emergency medicine Australasia : EMA*. 2015;27(3):187-91.

Previous Studies on Chronic Disease Compliance

COPD

8. Aaron SD, Vandemheen KL, Fergusson D, Maltais F, Bourbeau J, Goldstein R, Balter M, O'Donnell D, McIvor A, Sharma S, Bishop G, Anthony J, Cowie R, Field S, Hirsch A, Hernandez P, Rivington R, Road J, Hoffstein V, Hodder R, Marciniuk D, McCormack D, Fox G, Cox G, Prins HB, Ford G, Bleskie D, Doucette S, Mayers I, Chapman K, Zamel N, FitzGerald M. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. *Annals of internal medicine*. 2007;146(8):545-55.
9. Khdour MR, Kidney JC, Smyth BM, McElnay JC. Clinical pharmacy-led disease and medicine management programme for patients with COPD. *British journal of clinical pharmacology*. 2009;68(4):588-98.
10. Dhamane AD, Schwab P, Hopson S, Moretz C, Annavarapu S, Burslem K, Renda A, Kaila S. Association between adherence to medications for COPD and medications for other chronic conditions in COPD patients. *International journal of chronic obstructive pulmonary disease*. 2016;12:115-22.
11. Neugaard BI, Priest JL, Burch SP, Cantrell CR, Foulis PR. Quality of care for veterans with chronic diseases: performance on quality indicators, medication use and adherence, and health care utilization. *Population health management*. 2011;14(2):99-106.
12. Karner C, Chong J, Poole P. Tiotropium versus placebo for chronic obstructive pulmonary disease. *Cochrane Database of Systematic Reviews*. 2014(7).
13. Yang IA, Clarke MS, Sim EHA, Fong KM. Inhaled corticosteroids for stable chronic obstructive pulmonary disease. *Cochrane Database of Systematic Reviews*. 2012(7).
14. Alsaeedi A, Sin DD, McAlister FA. The effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review of randomized placebo-controlled trials. *The American journal of medicine*. 2002;113(1):59-65.

Asthma

15. Williams LK, Pladevall M, Xi H, Peterson EL, Joseph C, Lafata JE, Ownby DR, Johnson CC. Relationship between adherence to inhaled corticosteroids and poor outcomes among adults with asthma. *The Journal of allergy and clinical immunology*. 2004;114(6):1288-93.
16. Souza-Machado A, Santos PM, Cruz AA. Adherence to treatment in severe asthma: predicting factors in a program for asthma control in Brazil. *The World Allergy Organization journal*. 2010;3(3):48-52.

17. Calverley PMA. Effect of Corticosteroids on Exacerbations of Asthma and Chronic Obstructive Pulmonary Disease. *Proceedings of the American Thoracic Society*. 2004;1(3):161-6.
18. Peytremann-Bridevaux I, Arditi C, Gex G, Bridevaux PO, Burnand B. Chronic disease management programmes for adults with asthma. *Cochrane Database of Systematic Reviews*. 2015(5).
19. Chauhan BF, Chartrand C, Ni Chroinin M, Milan SJ, Ducharme FM. Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children. *Cochrane Database of Systematic Reviews*. 2015(11).
20. Gatheral TL, Rushton A, Evans DJW, Mulvaney CA, Halcovitch NR, Whiteley G, Eccles FJR, Spencer S. Personalised asthma action plans for adults with asthma. *Cochrane Database of Systematic Reviews*. 2017(4).

Atrial Fibrillation

21. Kim H, Kim TH, Cha MJ, Lee JM, Park J, Park JK, Kang KW, Shim J, Uhm JS, Kim J, Park HW, Choi EK, Kim JB, Kim C, Lee YS, Joung B. A Prospective Survey of Atrial Fibrillation Management for Real-world Guideline Adherence: COMparison study of Drugs for symptom control and complication prEvention of Atrial Fibrillation (CODE-AF) Registry. *Korean Circ J*. 2017;47(6):877-87.
22. Obamiro KO, Chalmers L, Lee K, Bereznicki BJ, Bereznicki LR. Adherence to Oral Anticoagulants in Atrial Fibrillation: An Australian Survey. *Journal of cardiovascular pharmacology and therapeutics*. 2018;23(4):337-43.

Heart Failure

23. Fitzgerald AA, Powers JD, Ho PM, Maddox TM, Peterson PN, Allen LA, Masoudi FA, Magid DJ, Havranek EP. Impact of medication nonadherence on hospitalizations and mortality in heart failure. *Journal of cardiac failure*. 2011;17(8):664-9.
24. Tsuyuki RT, McKelvie RS, Arnold JM, Avezum An, Barretto AC, Carvalho AC, Isaac DL, Kitching AD, Piegas LS, Teo KK, et al. Acute precipitants of congestive heart failure exacerbations. *Archives of internal medicine*. 2001;161(19):2337-42.
25. Unverzagt S, Meyer G, Mittmann S, Samos F-A, Unverzagt M, Prondzinsky R. Improving Treatment Adherence in Heart Failure. *Deutsches Arzteblatt international*. 2016;113(25):423-30.
26. Faris RF, Flather M, Purcell H, Poole-Wilson PA, Coats AJS. Diuretics for heart failure. *Cochrane Database of Systematic Reviews*. 2012(2).
27. Flather MD, Yusuf S, Kober L, Pfeffer M, Hall A, Murray G, Torp-Pedersen C, Ball S, Pogue J, Moye L, Braunwald E. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. *Lancet (London, England)*. 2000;355(9215):1575-81.
28. Ruppap TM, Cooper PS, Mehr DR, Delgado JM, Dunbar-Jacob JM. Medication Adherence Interventions Improve Heart Failure Mortality and Readmission Rates: Systematic Review and

Meta-Analysis of Controlled Trials. Journal of the American Heart Association. 2016;5(6):e002606.

Improving Guideline Compliance and Medication Adherence

29. Ward MM, Yankey JW, Vaughn TE, BootsMiller BJ, Flach SD, Watrin S, Doebbeling BN. Provider adherence to COPD guidelines: relationship to organizational factors. Journal of evaluation in clinical practice. 2005;11(4):379-87.
30. Oosterom-Calo R, van Ballegooijen AJ, Terwee CB, te Velde SJ, Brouwer IA, Jaarsma T, Brug J. Determinants of adherence to heart failure medication: a systematic literature review. Heart failure reviews. 2013;18(4):409-27.
31. Lemay J, Waheedi M, Al-Sharqawi S, Bayoud T. Medication adherence in chronic illness: do beliefs about medications play a role? Patient preference and adherence. 2018;12:1687-98.
32. Pagès-Puigdemont N, Manges MA, Masip M, Gabriele G, Fernández-Maldonado L, Blancafort S, Tuneu L. Patients' Perspective of Medication Adherence in Chronic Conditions: A Qualitative Study. Advances in therapy. 2016;33(10):1740-54.
33. Ruppert TM, Cooper PS, Mehr DR, Delgado JM, Dunbar-Jacob JM. Medication Adherence Interventions Improve Heart Failure Mortality and Readmission Rates: Systematic Review and Meta-Analysis of Controlled Trials. Journal of the American Heart Association. 2016;5(6):e002606.
34. Bryant J, McDonald VM, Boyes A, Sanson-Fisher R, Paul C, Melville J. Improving medication adherence in chronic obstructive pulmonary disease: a systematic review. Respiratory research. 2013;14:109.
35. Oberje EJ, de Kinderen RJ, Evers SM, van Woerkum CM, de Bruin M. Cost effectiveness of medication adherence-enhancing interventions: a systematic review of trial-based economic evaluations. Pharmacoeconomics. 2013;31(12):1155-68.
36. van Boven JFM, Cushen B, Sulaiman I, Greene G, MacHale E, Mokoka MC, Doyle F, Reilly RB, Bennett K, Costello RW. Personalising adherence-enhancing interventions using a smart inhaler in patients with COPD: an exploratory cost-effectiveness analysis. NPJ Prim Care Respir Med. 2018;28(1):24-.